Amgen's 0.74 Billion Dollar Volume Climbs to 125th in Market Activity as Leadership Showcases Innovation at Morgan Stanley Conference

On September 4, 2025, Amgen (NASDAQ: AMGN) closed with a 1.32% decline, trading at a volume of $0.74 billion, ranking 125th in market activity for the day. The biopharmaceutical giant announced its participation in the Morgan Stanley 23rd Annual Global Healthcare Conference on September 9, 2025. Peter Griffith, executive vice president and CFO, and Kave Niksefat, senior vice president of Global Marketing and Access, will lead the presentation. A live webcast of the event will be accessible via Amgen’s Investor Relations website, with an archived replay available for 90 days post-event.

Amgen, a pioneer in biotechnology, emphasized its commitment to advancing treatments for cancer, cardiovascular diseases, and rare conditions. The company remains a key component of the Dow Jones Industrial Average and Nasdaq-100 Index, reflecting its market influence. The conference presentation aligns with its strategy to engage stakeholders through regular updates on business developments and pipeline progress.

The webcast will provide investors and the public with direct access to leadership insights, reinforcing transparency in corporate communications. Amgen’s participation in such high-profile events underscores its role as a leader in healthcare innovation, with a focus on leveraging genetic data and cutting-edge technology to address unmet medical needs.

Analysis in progress...